Appendix 4E and 2026 Annual Report
Filed with ASX · · 94 pages · English
Summary by 6ix AI
The report highlights a significant increase in other income, while the loss from ordinary activities after tax has decreased compared to the previous year. No dividends were declared during the financial period, and the company reported a notable improvement in net assets.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Neurizon Enters Strategic R&D Financing Facility
- HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
- HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27
- Neurizon executes long-term supply agreement with Elanco
- HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
Later from Neurizon Therapeutics
- Neurizon Appoints Chief Executive Officer
- NIH funds Expanded Access Program for NUZ-001 in ALS
- Neurizon Announces Partial Redemption of Convertible Notes
- FDA Type C Feedback, HEALEY trial potentially registrational
- Appendix 4C & Quarterly Update
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics